⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ARVN News
Arvinas, Inc
HPK1 Inhibitors Pipeline Insight 2026: Immuno-Oncology Innovation Fuels Clinical Development, Strategic Partnerships and Future Growth Opportunities
globenewswire.com
ARVN
Actithera significantly strengthens leadership team and Board as Company advances towards clinical development
globenewswire.com
CRSP
ARVN
AMGN
Sofinnova Investments Announces the Appointment of Dr. Merdad Parsey as Executive Partner
businesswire.com
GILD
REGN
MRK
ARDX
ARVN
IMAX
Arvinas to Participate in Upcoming Investor Conferences
globenewswire.com
ARVN
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
ARVN
Global PROTAC Targeted Protein Degraders Market Outlook 2026-2030: Covers Indications, Trial Phases, Combinations, and Technology Platforms
globenewswire.com
ARVN
Global Fusion Biopsy Market to Register Sustainable Growth at a CAGR of ~6% by 2034 | DelveInsight
globenewswire.com
BSX
CAH
MDT
GEHC
XRAY
AMGN
AZN
BMY
LLY
MRK
PFE
SNY
TEVA
JNJ
BIIB
GILD
NVS
GOOG
MSFT
IBM
NVDA
INTC
AMD
QCOM
AMAT
MU
NXPI
ASML
ADI
LRCX
KLAC
CDNS
SNPS
MCHP
ON
STM
MRVL
AEHR
TER
PAYX
CTAS
WST
ZBRA
VRSN
NOW
CRM
ADBE
PANW
CSCO
ACN
HPQ
ORCL
SAP
PTC
ALGN
ESTC
DDOG
SMCI
EXAS
CRSP
EDIT
BEAM
NTLA
REGN
VRTX
XOM
CVX
SHEL
BABA
JD
PDD
NTES
BIDU
IQ
BILI
VIPS
HTHT
EDU
TAL
MELI
AMZN
NFLX
DIS
CMCSA
VZ
T
SIRI
GOOGL
AAPL
META
TSLA
GE
PHI
BRKR
AUR
FONR
BFLY
CRI
EXEL
TAK
ABSI
JHG
XNCR
MOD
ARVN
CLAR
BNTX
FOR
ORIC
COOK
OWL
MTA
SKIN
HYPR
ALLT
MAGN
Form 8-K
sec.gov
ARVN
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
ARVN
RIGL
Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
globenewswire.com
ARVN